SURPASS ET: ropeginterferon alfa-2b vs anagrelide for second-line essential thrombocythemia VJHemOnc – Video Journal of Hematology & HemOnc 1:28 1 year ago 254 Далее Скачать
The SURPASS-ET study: evaluating novel treatment approaches in ET VJHemOnc – Video Journal of Hematology & HemOnc 2:05 2 years ago 206 Далее Скачать
SURPASS ET: P1101 in essential thrombocythemia VJHemOnc – Video Journal of Hematology & HemOnc 1:57 3 years ago 1 276 Далее Скачать
Upcoming trials and novel agents in MPNs VJHemOnc – Video Journal of Hematology & HemOnc 1:44 2 years ago 362 Далее Скачать
SURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemia VJHemOnc – Video Journal of Hematology & HemOnc 1:59 2 years ago 1 169 Далее Скачать
Current treatment approaches in ET and an insight into the SURPASS-ET trial VJHemOnc – Video Journal of Hematology & HemOnc 1:46 2 years ago 90 Далее Скачать
ESSENTIAL THROMBOCYTHEMIA Pathogenesis. Mechanism of clinical symptoms. Splenomegaly. Thrombosis Foxterrier 11:17 2 years ago 880 Далее Скачать
Unmet needs and therapeutic strategies in essential thrombocythemia VJHemOnc – Video Journal of Hematology & HemOnc 3:29 2 years ago 717 Далее Скачать
ESSENTIAL THROMBOCYTHEMIA Etiology. CALR (Calreticulin) MPL JAK2 mutation. Molecular pathogenesis Foxterrier 12:42 2 years ago 1 675 Далее Скачать
MPN Clinical Trial Updates for Physicians MPN Advocacy & Education International 2:56:57 3 years ago 640 Далее Скачать
